与首次给药相比，长效胰岛素类似物甘精胰岛素在1型糖尿病患者使用1周后的药代动力学和药效学。 - Suppr

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

作者信息

Porcellati Francesca, Rossetti Paolo, Ricci Natalia Busciantella, Pampanelli Simone, Torlone Elisabetta, Campos Susana Hernandez, Andreoli Anna Marinelli, Bolli Geremia B, Fanelli Carmine G

机构信息

University of Perugia, Department of Internal Medicine, Section of Internal Medicine, Endocrinology, and Metabolism, via E. Dal Pozzo, 06126 Perugia, Italy.

出版信息

Diabetes Care. 2007 May;30(5):1261-3. doi: 10.2337/dc06-2208. Epub 2007 Feb 15.

DOI:10.2337/dc06-2208

PMID:17303785

Abstract

摘要

相似文献

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

Diabetes Care. 2007 May;30(5):1261-3. doi: 10.2337/dc06-2208. Epub 2007 Feb 15.

Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

Diabetes Care. 2007 Oct;30(10):2447-52. doi: 10.2337/dc07-0002. Epub 2007 Jul 10.

Insulin glargine: a long-acting insulin for diabetes mellitus.

Issues Emerg Health Technol. 2003 Nov(52):1-4.

[Long-acting insulin analog, glargine, in the treatment of type 1 diabetes].

Duodecim. 2004;120(1):88-92.

Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.

Pediatr Diabetes. 2008 Jun;9(3 Pt 2):83-90. doi: 10.1111/j.1399-5448.2007.00341.x. Epub 2008 Jan 25.

A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.

Pediatrics. 2008 Mar;121(3):e466-72. doi: 10.1542/peds.2007-1679. Epub 2008 Feb 25.

Insulin detemir (levemir), a new long-acting insulin.

Med Lett Drugs Ther. 2006 Jul 3;48(1238):54-5.

Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.

Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):378-85. doi: 10.1055/s-0029-1225337. Epub 2009 Jul 23.

Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.

Pediatrics. 2008 Sep;122(3):675-6; author reply 676. doi: 10.1542/peds.2008-1636.

[Soluble long-acting insulin analogues].

Nihon Rinsho. 1997 Nov;55 Suppl:306-9.

引用本文的文献

Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project.

Mayo Clin Proc Innov Qual Outcomes. 2024 May 22;8(3):293-300. doi: 10.1016/j.mayocpiqo.2024.03.008. eCollection 2024 Jun.

The 2021-2022 position of Brazilian Diabetes Society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice.

Diabetol Metab Syndr. 2022 Dec 12;14(1):189. doi: 10.1186/s13098-022-00949-z.

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.

Diabetes Obes Metab. 2021 Jan;23(1):166-174. doi: 10.1111/dom.14212. Epub 2020 Oct 19.

Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.

PLoS One. 2018 Aug 16;13(8):e0202007. doi: 10.1371/journal.pone.0202007. eCollection 2018.

Insulin analogues in type 1 diabetes mellitus: getting better all the time.

Nat Rev Endocrinol. 2017 Jul;13(7):385-399. doi: 10.1038/nrendo.2017.39. Epub 2017 Apr 21.

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.

Diabetes Obes Metab. 2017 Jan;19(1):3-12. doi: 10.1111/dom.12782. Epub 2016 Sep 26.

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.

Diabetes Obes Metab. 2017 Jan;19(1):33-39. doi: 10.1111/dom.12759. Epub 2016 Sep 8.

The evolution of insulin glargine and its continuing contribution to diabetes care.

Drugs. 2014 Jun;74(8):911-27. doi: 10.1007/s40265-014-0226-4.

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Diabetes Care. 2012 Dec;35(12):2626-30. doi: 10.2337/dc12-0270. Epub 2012 Oct 23.

International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.

Diabetes Technol Ther. 2011 Sep;13(9):967-79. doi: 10.1089/dia.2011.0179.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

作者信息

Porcellati Francesca, Rossetti Paolo, Ricci Natalia Busciantella, Pampanelli Simone, Torlone Elisabetta, Campos Susana Hernandez, Andreoli Anna Marinelli, Bolli Geremia B, Fanelli Carmine G

机构信息

University of Perugia, Department of Internal Medicine, Section of Internal Medicine, Endocrinology, and Metabolism, via E. Dal Pozzo, 06126 Perugia, Italy.

出版信息

Diabetes Care. 2007 May;30(5):1261-3. doi: 10.2337/dc06-2208. Epub 2007 Feb 15.

DOI:10.2337/dc06-2208

PMID:17303785

Abstract

摘要

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

作者信息

机构信息

出版信息

相似文献

引用本文的文献